SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $8.87 and traded as high as $24.89. SELLAS Life Sciences Group shares last traded at $19.15, with a volume of 119,833,416 shares.
Top SELLAS Life Sciences Group Stories
Investors following SLS have been watching these stories:
- Positive Sentiment: REGAL showed a 41% reduction in risk of death versus best available treatment, with median overall survival of 24.0 months compared with 14.7 months (hazard ratio 0.59; p=0.035). GPS was generally well tolerated, with no new safety signals reported. SELLAS REGAL trial results
- Positive Sentiment: SELLAS plans to discuss the results and potential accelerated filing with the FDA, and is preparing for a Biologics License Application submission in the first half of 2027. The trial win provides Phase 3 validation for GPS, though approval is not assured. SELLAS Phase 3 trial coverage
- Negative Sentiment: SELLAS proposed a $150 million underwritten public offering after the rally. Issuing shares could dilute existing shareholders, and reports said the stock fell on the financing announcement. Proposed public offering
Analyst Ratings Changes
SLS has been the subject of a number of research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research note on Thursday, October 15th. Alliance Global Partners reaffirmed a "buy" rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, SELLAS Life Sciences Group presently has a consensus rating of "Hold" and a consensus target price of $10.00.
Check Out Our Latest Stock Analysis on SELLAS Life Sciences Group
SELLAS Life Sciences Group Stock Performance
The business has a 50 day simple moving average of $11.01 and a 200-day simple moving average of $8.87. The firm has a market cap of $3.90 billion, a price-to-earnings ratio of -95.75 and a beta of 2.73.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05).
Institutional Investors Weigh In On SELLAS Life Sciences Group
Institutional investors have recently bought and sold shares of the stock. Nykredit A S bought a new position in SELLAS Life Sciences Group during the 2nd quarter valued at $27,000. GAMMA Investing LLC boosted its holdings in SELLAS Life Sciences Group by 293.2% during the 3rd quarter. GAMMA Investing LLC now owns 2,186 shares of the company's stock worth $27,000 after acquiring an additional 1,630 shares during the last quarter. Allworth Financial LP grew its stake in shares of SELLAS Life Sciences Group by 1,107.2% in the 3rd quarter. Allworth Financial LP now owns 5,698 shares of the company's stock worth $70,000 after acquiring an additional 5,226 shares in the last quarter. Sterling Capital Management LLC grew its stake in shares of SELLAS Life Sciences Group by 900.8% in the 3rd quarter. Sterling Capital Management LLC now owns 6,635 shares of the company's stock worth $82,000 after acquiring an additional 5,972 shares in the last quarter. Finally, City State Bank bought a new stake in shares of SELLAS Life Sciences Group in the 3rd quarter worth $100,000. Institutional investors own 17.38% of the company's stock.
SELLAS Life Sciences Group Company Profile
(
Get Free Report)
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms' tumor 1 (WT1) protein, which is found in several types of cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.